Regeneron Pharmaceuticals, Inc.
REGN · Healthcare
$823.82
Cargando gráfico…
Noticias
Últimos titulares de esta acción
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - SNS Insider
The global atopic dermatitis drugs market is projected to grow from USD 15.92 billion in 2025 to USD 33.42 billion by 2035, driven by increased adoption of biologic therapies, JAK inhibitors, and novel treatments. North America leads with 36% market share, while Asia-Pacific shows the fastest growth. Biologics dominate with 42% market share, though high costs and JAK inhibitor safety warnings present challenges.
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.
REGN 12-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
A securities class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly making false and misleading statements about its Phase 3 clinical trial of Fianlimab for melanoma treatment. The company reportedly failed to disclose that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. After initially expressing confidence in the trial, Regeneron altered the trial protocol in November 2025 without timely disclosure and ultimately announced on May 15, 2026 that the trial failed to reach statistical significance, resulting in an $11 billion market cap loss.
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging that the company made materially false and misleading statements regarding its Phase III Fianlimab-Libtayo study. The complaint claims the study's preliminary statistical assumptions were flawed, the treatment arm showed no meaningful clinical differentiation from standard therapies, and the study was unlikely to achieve statistical significance on its primary endpoint. The class period covers purchases between August 1, 2025 and May 15, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging that the company made materially false and misleading statements regarding its Phase III Fianlimab-Libtayo study. The complaint claims the study's preliminary statistical assumptions were flawed, the treatment arm showed no meaningful clinical differentiation from standard therapies, and the study was unlikely to achieve statistical significance on its primary endpoint. Investors who purchased Regeneron securities between August 1, 2025 and May 15, 2026 are encouraged to join the case.